All In Biotech

Drug Trial Radar · NCT07659795

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, With and Without an Anti-EGFR Antibody, and With an Anti-EGFR Antibody and Chemotherapy, in Patients With Metastatic KRAS G12D-Mutated Colorectal Adenocarcinoma (TARGET-D 203)

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Jul 28, 2026

Primary completion

Jun 2027

Study completion Dec 2028

Sponsor

Lead sponsor
Verastem, Inc.Industry
Sponsor type
Industry
First posted
Jun 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab or panitumumab and cetuximab plus mFOLFOX in patients with metastatic KRAS G12D - mutated Colorectal Cancer

Conditions

  • Colorectal Cancer

Interventions

  • VS-7375Drug

    Taken by mouth

  • cetuximabDrug

    Intravenous infusion

  • panitumumabDrug

    Intravenous infusion

  • Cetuximab + mFOLFOX6Drug

    Intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Confirmed ORR by blinded independent central review (BICR) per RESIST v1.1 - 2L CRC onlyTime frame: 6 months
  2. To characterize the safety and tolerability of VS-7375 monotherapy or in combination with cetuximab or panitumumab, administered on a daily oral schedule in participants with KRAS G12D-mutated 2L+ CRCTime frame: 6 months
  3. To characterize the safety and tolerability of VS-7375 in combination with cetuximab + mFOLFOX, administered on a daily oral schedule in participants with KRAS G12D-mutated 1L CRCTime frame: 6 months

Locations

35 sites in 5 countries. Site status is shown where the registry gives one.

  • HonorHealth

    Scottsdale, Arizona · Recruiting

  • START Los Angeles

    Los Angeles, California · Recruiting

  • Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • Valkyrie Clinical Trials (contact for more locations)

    Los Angeles, California · Recruiting

  • BRCR - Coral Springs

    Coral Springs, Florida · Recruiting

  • BRCR - Tamarac

    Tamarac, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Indiana University, Simon Comprehensive Cancer Center

    Indianapolis, Indiana · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • START Midwest

    Grand Rapids, Michigan · Recruiting

  • Washington University

    St Louis, Missouri · Recruiting

  • START New Jersey

    East Brunswick, New Jersey · Recruiting

  • Perlmutter Cancer Center at NYU Langone Health (contact for more locations)

    New York, New York · Recruiting

  • University of North Carolina

    Chapel Hill, North Carolina · Recruiting

  • Case Western, University Hospitals Cleveland Medical Center

    Cleveland, Ohio · Recruiting

  • Sarah Cannon Research Institute Oncology Partners

    Nashville, Tennessee · Recruiting

  • START Dallas Fort Worth

    Fort Worth, Texas · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Huntsman Cancer Institute - University of Utah

    Salt Lake City, Utah · Recruiting

  • START Mountain Region

    West Valley City, Utah · Recruiting

  • UVA Comprehensive Cancer Center

    Charlottesville, Virginia · Recruiting

  • Virginia Cancer Specialists

    Fairfax, Virginia · Recruiting

  • Virginia Mason Medical Center

    Seattle, Washington · Recruiting

  • University of Wisconsin

    Madison, Wisconsin · Recruiting

  • Macquarie University Hospital

    Macquarie Park, New South Wales, Australia · Recruiting

  • Calvary Mater Newcastle

    Waratah, New South Wales, Australia · Recruiting

  • Icon Cancer Centre Townsville

    Hyde Park, Queensland, Australia · Recruiting

  • Icon Cancer Centre South Brisbane

    South Brisbane, Queensland, Australia · Recruiting

  • Icon Cancer Centre Adelaide

    Kurralta Park, South Australia, Australia · Recruiting

  • Icon Cancer Centre Hobart

    Hobart, Tasmania, Australia · Recruiting

  • Alfred Hospital

    Melbourne, Victoria, Australia · Recruiting

  • CHU UCL Namur Site St. Elisabeth

    Namur, Belgium · Recruiting

  • Centre Georges François Leclerc

    Dijon, France, France · Recruiting

  • START Barcelona - HM Nou Delfos

    Barcelona, Spain · Recruiting

  • Hospital Universitario Ramón y Cajal

    Madrid, Spain, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.